DNA X, Inc. 8-K

What Happened DNA X, Inc. (SONM) filed an 8-K reporting that Mike Mulica was appointed acting chief executive officer effective February 9, 2026, and designated the Company’s principal executive officer. The board’s compensation committee approved amendments to executive employment terms: Mulica’s base salary was increased and he received an equity award; the Company also amended CFO Clay Crolius’s agreement following a completed asset sale. The changes were documented in amendments dated February 9, 2026.

Key Details

• Acting CEO: Mike Mulica appointed effective February 9, 2026; Mulica has been with the company since April 2021 and served as executive chairman as of October 16, 2025.
• CEO pay and equity: Mulica’s annual base salary increased to $450,000 effective January 30, 2026; granted 50,000 RSUs vesting in equal monthly installments over one year, subject to continued service.
• CFO amendment: Clay Crolius’s agreement amended on February 9, 2026; the Company’s January 23, 2026 asset sale is a triggering event; Crolius received 35,000 RSUs vesting monthly over one year.
• COBRA coverage: Post-termination COBRA premium reimbursement—up to 12 months for Mulica and up to 6 months for Crolius—subject to customary early-termination conditions.

Why It Matters This filing signals a leadership transition (an acting CEO) and concrete changes to executive compensation that can affect the company’s operating costs and executive incentives. Equity grants (RSUs) and salary changes align management pay with continued service over the next year, while the CFO amendment ties contractual terms to the recently completed asset sale (January 23, 2026). Investors should note these governance and compensation updates as they consider management continuity and potential near-term expense recognition.